Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biochemical and clinical pharmacology of 5-fluorouracil.

Oncology (Williston Park, N.Y.) - 1 Oct 1998

Schilsky R L

Abstract excerpt

The cellular and clinical pharmacology of fluoropyrimidines is characterized by marked interpatient variability in tumor response and patient tolerance. Understanding the metabolic pathways followed by 5-fluorouracil (5-FU) has led to new strategies to optimize therapy with these important agents. The "fluoropyrimidine phenotype" of tumor cells can be used to determine whether therapy with these agents is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Antimetabolites, Antineoplastic
Share to DNA, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Fluorouracil

Share to Neoplasms

Share to Oxidoreductases

Share to Phenotype

Source

Identifiers

PMID: 9830619

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biochemical and clinical pharmacology of 5-fluorouracil.PMID 9830619Read ↗

The Role of Pharmacogenetics and Pharmacogenomics in Cancer Chemotherapy with 5-FluorouracilSemantic proximity Read ↗

5-Fluorouracil: mechanisms of action and clinical strategiesSemantic proximity Read ↗

Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.Semantic proximity Read ↗

Phenotype versus genotype to optimize cancer dosing in the clinical setting-focus on 5-fluorouracil and tyrosine kinase inhibitors.Semantic proximity Read ↗

Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration.Semantic proximity Read ↗

Pharmacogenetics in cancer chemotherapy: balancing toxicity and response.Semantic proximity Read ↗

Implications of Dihydropyrimidine Dehydrogenase on 5-Fluorouracil Pharmacogenetics and PharmacogenomicsSemantic proximity Read ↗

Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen.Semantic proximity Read ↗

How may anticancer chemotherapy with fluorouracil be individualised?Semantic proximity Read ↗

Dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil associated toxicity.Semantic proximity Read ↗

Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy.Semantic proximity Read ↗

FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.